OBJECTIVE: Previously an upregulation of E-cadherin and its associated molecules alpha-catenin, beta-catenin and plakoglobin has been demonstrated in clinically overt inflammatory bowel disease (IBD). The aim of this study was to investigate the expression of the E-cadherin/catenin complex in subclinically inflamed bowel mucosa from spondyloarthropathy (SpA) patients. METHODS: Ileal and colonic biopsy specimens from 19 SpA patients with subclinical inflammatory gut lesions and from seven controls were stained with monoclonal antibodies against E-cadherin, beta-catenin and plakoglobin and a polyclonal antibody against alpha-catenin. E-cadherin mRNA was detected using a riboprobe. Inflammation was histologically classified into acute, chronic active and chronic quiescent forms. RESULTS: In acute and chronic active bowel inflammation of SpA patients, upregulation of the E-cadherin/catenin glycoprotein complex could be observed. Chronic lesions in a quiescent state did not show such an upregulation. Furthermore, chronic inflammation was associated with an increase in E-cadherin mRNA. CONCLUSIONS: As some of the SpA patients with subclinical gut inflammation develop IBD, upregulation of the E-cadherin/catenin complex in inflamed bowel mucosa from SpA patients may point to early cellular changes in the development of IBD. However, at present it cannot be excluded that increased E-cadherin/catenin complex expression is a bystander phenomenon of active inflammation.
OBJECTIVE: Previously an upregulation of E-cadherin and its associated molecules alpha-catenin, beta-catenin and plakoglobin has been demonstrated in clinically overt inflammatory bowel disease (IBD). The aim of this study was to investigate the expression of the E-cadherin/catenin complex in subclinically inflamed bowel mucosa from spondyloarthropathy (SpA) patients. METHODS: Ileal and colonic biopsy specimens from 19 SpA patients with subclinical inflammatory gut lesions and from seven controls were stained with monoclonal antibodies against E-cadherin, beta-catenin and plakoglobin and a polyclonal antibody against alpha-catenin. E-cadherin mRNA was detected using a riboprobe. Inflammation was histologically classified into acute, chronic active and chronic quiescent forms. RESULTS: In acute and chronic active bowel inflammation of SpA patients, upregulation of the E-cadherin/catenin glycoprotein complex could be observed. Chronic lesions in a quiescent state did not show such an upregulation. Furthermore, chronic inflammation was associated with an increase in E-cadherin mRNA. CONCLUSIONS: As some of the SpA patients with subclinical gut inflammation develop IBD, upregulation of the E-cadherin/catenin complex in inflamed bowel mucosa from SpA patients may point to early cellular changes in the development of IBD. However, at present it cannot be excluded that increased E-cadherin/catenin complex expression is a bystander phenomenon of active inflammation.
Authors: N A Wright; R Poulsom; G Stamp; S Van Noorden; C Sarraf; G Elia; D Ahnen; R Jeffery; J Longcroft; C Pike Journal: Gastroenterology Date: 1993-01 Impact factor: 22.682
Authors: Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants Journal: Rheumatol Int Date: 2008-09-26 Impact factor: 2.631
Authors: Filip De Keyser; Dominique Baeten; Filip Van den Bosch; Martine De Vos; Claude Cuvelier; Herman Mielants; Eric Veys Journal: Curr Rheumatol Rep Date: 2002-12 Impact factor: 4.592
Authors: Filip De Keyser; Dominique Baeten; Filip Van den Bosch; Elli Kruithof; Gust Verbruggen; Herman Mielants; Eric Veys Journal: Drugs Date: 2004 Impact factor: 9.546
Authors: H Peeters; B Vander Cruyssen; D Laukens; P Coucke; D Marichal; M Van Den Berghe; C Cuvelier; E Remaut; H Mielants; F De Keyser; M D Vos Journal: Ann Rheum Dis Date: 2004-09 Impact factor: 19.103
Authors: D Laukens; H Peeters; B V Cruyssen; T Boonefaes; D Elewaut; F De Keyser; H Mielants; C Cuvelier; E M Veys; K Knecht; P Van Hummelen; E Remaut; L Steidler; M De Vos; P Rottiers Journal: Ann Rheum Dis Date: 2006-02-13 Impact factor: 19.103